Arthritis & Rheumatology最新文献

{"title":"Reply to: Limitations in the Real‐World Emulation of the HORIZON Pivotal Fracture Trial","authors":"Elvira D'Andrea, Shirley Wang","doi":"10.1002/art.43103","DOIUrl":"https://doi.org/10.1002/art.43103","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"101 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Avoiding placebo as control treatment in rheumatology trials: can we do better?","authors":"Maarten Boers","doi":"10.1002/art.43107","DOIUrl":"https://doi.org/10.1002/art.43107","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"23 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limitations in the Real‐World Emulation of the HORIZON Pivotal Fracture Trial","authors":"Peng Shih‐Kuei, Poi Kuo, James Cheng‐Chung Wei","doi":"10.1002/art.43102","DOIUrl":"https://doi.org/10.1002/art.43102","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"56 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142936750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Connections","authors":"","doi":"10.1002/art.42870","DOIUrl":"10.1002/art.42870","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"77 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.42870","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142904870","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Journal Club","authors":"","doi":"10.1002/art.42868","DOIUrl":"10.1002/art.42868","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"77 1","pages":""},"PeriodicalIF":11.4,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.42868","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142905022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Distinct pathophysiological pathways support stratification of Sjögren's disease based on symptoms, clinical, and routine biological data","authors":"Yann Nguyen, Maxime Beydon, Jacques‐Eric Gottenberg, Jacques Morel, Aleth Perdriger, Emmanuelle Dernis, Divi Cornec, Valérie Devauchelle‐Pensec, Damien Sène, Philippe Dieudé, Marion Couderc, Anne‐Laure Fauchais, Claire Larroche, Olivier Vittecoq, Carine Salliot, Eric Hachulla, Véronique Le Guern, Xavier Mariette, Raphaèle Seror, Gaëtane Nocturne","doi":"10.1002/art.43096","DOIUrl":"https://doi.org/10.1002/art.43096","url":null,"abstract":"ObjectiveRecently, three distinct phenotypes of Sjögren's disease (SjD) patients have been described, based on cluster analysis: B‐cell active with low symptoms (BALS), high systemic activity (HSA), and low systemic activity with high symptoms (LSAHS). We aimed to assess whether these clusters were associated with distinct biomarkers and the prognostic value of IFN signature.MethodsThe ASSESS cohort is a 20‐year prospective cohort of SjD patients. The following biomarkers were compared: IFN‐α2, IFN‐γ, CXCL10, CXCL13, BAFF, IL7, FLT3, CCL19, and TNFRII. IFN signature was assessed using transcriptomic analysis. We then compared systemic and symptomatic evolution, and the risk of new immunosuppressant prescription and of lymphoma, according to the IFN signature across the three clusters.Results395 patients (94% female, median age 53 [43‐63] years) were included. Higher levels of CXCL‐13, IL7, and TNF‐RII levels were found in the BALS and HSA clusters compared to the LSAHS cluster. A high IFN signature was mainly found in the BALS cluster (57%, vs. 48%, and 38% in the HSA and LSAHS clusters, respectively). This IFN signature was mainly driven by type I IFN, with higher levels of IFN‐ α2. In the BALS cluster, a high IFN signature was associated with a higher risk of new immunosuppressant treatment (HR 9.38; 95% CI 1.22‐72.16). All lymphoma occurred in patients with high IFN signature.ConclusionThe three SjD clusters displayed distinct expression of IFN signature, and markers of T‐ and B‐cell activation, confirming distinct pathophysiological mechanisms. High IFN signature could predict systemic evolution in the BALS cluster.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"3 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atherosclerotic plaque progression and incident cardiovascular events in a 10‐year prospective study of patients with Systemic Lupus Erythematosus: the impact of persistent cardiovascular risk factor target attainment and sustained DORIS remission","authors":"Nikolaos Papazoglou, Petros P. Sfikakis, Maria G. Tektonidou","doi":"10.1002/art.43097","DOIUrl":"https://doi.org/10.1002/art.43097","url":null,"abstract":"ObjectiveCardiovascular disease is a leading cause of mortality in Systemic Lupus Erythematosus (SLE). We assessed atherosclerotic plaque progression and incident cardiovascular events in SLE patients over a 10‐year follow‐up.MethodsWe prospectively analyzed 738 carotid ultrasound measurements (413 in SLE patients and 325 in age/sex‐matched healthy controls [HC]) to assess new plaque development from baseline to 3‐, 7‐, and 10‐year follow‐up. Multivariate mixed Poisson regression models examined potential predictors of plaque progression, including patient characteristics, Systemic Coronary Risk Evaluation (SCORE), traditional cardiovascular risk factor (CVRF) target attainment, Definition of Remission in SLE (DORIS), medications, and persistent triple antiphospholipid antibody (aPL) positivity during follow‐up. Ten‐year incident cardiovascular events were recorded, and univariate Cox regression analysis assessed potential associations.ResultsSLE patients had a 2.3‐fold higher risk of carotid plaque progression than HC (Incidence Rate Ratio [IRR]: 2.26; p=0.002). Plaque progression risk in SLE was reduced by 32% (IRR: 0.68, p=0.004) per each sustainedly attained CVRF target during follow‐up, including blood pressure, lipids, smoking, body weight, and physical activity. DORIS achievement ≥75% of follow‐up was associated with a 43% decrease in atherosclerosis progression risk (IRR: 0.57; p=0.033). Ten‐year risk of incident cardiovascular events was higher in SLE than HC individuals (eight versus one event, permutation‐based log‐rank p=0.036) and was associated with persistent triple aPL positivity.ConclusionPatients with SLE experience a 2.3‐fold higher 10‐year atherosclerosis progression risk than HC, mitigated by sustained CVRF control and prolonged clinical remission. Persistent triple aPL positivity is associated with increased incidence of CVD events.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"8 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Absence of Functional Autoantibodies Targeting Angiotensin II Type 1 Receptor (AT1R) and Endothelin‐1 Type A Receptor (ETAR) in Circulation and Purified IgG from Patients with Systemic Sclerosis","authors":"Wieke M. van Oostveen, Eva M. Hoekstra, E.W. Nivine Levarht, Ilana B. Kotliar, Thomas P. Sakmar, René E.M. Toes, Jeska K. de Vries‐Bouwstra, Laura H. Heitman, Cynthia M. Fehres","doi":"10.1002/art.43099","DOIUrl":"https://doi.org/10.1002/art.43099","url":null,"abstract":"ObjectiveSystemic sclerosis (SSc) is a rare but severe autoimmune disease characterized by immune dysregulation, fibrosis, and vasculopathy. While previous studies have highlighted the presence of functional autoantibodies targeting the angiotensin II type 1 receptor (AT<jats:sub>1</jats:sub>R) and endothelin‐1 type A receptor (ET<jats:sub>A</jats:sub>R), leading to autoantibody‐mediated receptor stimulation and subsequent activation of endothelial cells (ECs), a comprehensive understanding of the direct interaction between these autoantibodies and their receptors is currently lacking. Moreover, existing data confirming the presence of these autoantibodies in SSc often rely on similar methodologies and assays. Our aim was to replicate previous findings and to investigate the functional effects of SSc patient‐derived IgG (SSc IgG) on AT<jats:sub>1</jats:sub>R‐ and ET<jats:sub>A</jats:sub>R signaling, the downstream EC response, as well as presence of AT<jats:sub>1</jats:sub>R‐binding autoantibodies in circulation.MethodsQuantitative PCR (qPCR) and cytokine ELISA, alongside a real‐time cell analyzer, were utilized to assess receptor‐specific functional characteristics of purified IgG from SSc patients (n=18). Additionally, a novel protein capture assay using solubilized epitope‐tagged AT<jats:sub>1</jats:sub>R was developed to detect AT<jats:sub>1</jats:sub>R‐binding autoantibodies in plasma samples from SSc patients (n=28) and healthy donors (n=14).ResultsNo evidence for EC activation in an AT<jats:sub>1</jats:sub>R‐ or ET<jats:sub>A</jats:sub>R‐dependent manner was revealed. Furthermore, stimulation with SSc IgG did not induce receptor activation nor alter GPCR signaling upon agonist stimulation in a model with receptor overexpression. Lastly, no AT<jats:sub>1</jats:sub>R‐binding autoantibodies were detected in plasma from SSc patients when using epitope‐tagged solubilized AT<jats:sub>1</jats:sub>R.ConclusionOverall, our study did not provide evidence to support the presence of AT<jats:sub>1</jats:sub>R‐ or ET<jats:sub>A</jats:sub>R‐activating autoantibodies in purified SSc IgG, nor AT<jats:sub>1</jats:sub>R‐binding autoantibodies in circulation of SSc patients.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"54 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Author Reply to Letter to the Editor","authors":"Wayne YW Lee, Rongliang Wong","doi":"10.1002/art.43100","DOIUrl":"https://doi.org/10.1002/art.43100","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"150 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disturbed spatial WNT activation – a potential driver of the reticularized skin phenotype in Systemic Sclerosis (SSc)","authors":"Sara Chenguiti Fakhouri, Honglin Zhu, Yi-Nan Li, Moritz Ronicke, Aleix Rius Rigau, Clara Dees, Laura Konstantinidis, Ralf Schmid, Alexandru-Emil Matei, Markus Eckstein, Carol Geppert, Ingo Ludolph, Alexander Kreuter, Michael Sticherling, Carola Berking, Raymund E. Horch, Georg Schett, Jörg H.W. Distler, Christina Bergmann","doi":"10.1002/art.43094","DOIUrl":"https://doi.org/10.1002/art.43094","url":null,"abstract":"Little is known on the mechanisms necessary to maintain the physiological adult human skin integrity. This study aims to quantitatively describe anatomical changes in systemic sclerosis (SSc)-skin compared to controls and investigate the underlying mechanisms.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"63 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2024-12-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142887128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}